论文部分内容阅读
据报道,糖尿病及其相关的代谢性疾病是新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)患者的主要合并症.这项临床研究旨在调查有或没有合并糖尿病的COVID-19患者的临床特征、影像学和实验室检查、并发症、治疗方法以及临床结局.这项回顾性研究纳入2020年1月12日至3月25日208例经实验室确认的COVID-19的住院患者(≥45岁).分析病历信息包括临床特征、影像学和实验室检查、并发症、治疗和临床结果.其中,96名(46.2％)患者患有2型糖尿病.在COVID-19合并2型糖尿病患者中,高血压(58.3％vs.31.2％)、冠心病(17.1％vs.8.0％)和慢性肾脏病(6.2％vs.0％)的共存率明显高于没有2型糖尿病的COVID-19患者.COVID-19合并2型糖尿病患者的CT胸部扫描异常频率和程度显著增加,包括毛玻璃样混浊(85.6％vs.64.9％,P<0.001)和双侧斑片状阴影(76.7％vs.37.8％,P<0.001).此外,患有糖尿病的COVID-19患者的血糖水平[7.23 mmol·L?1(IQR:5.80～9.29)vs.5.46 mmol·L?1(IQR:5.00～6.46)]、血液中低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)[2.21 mmol·L?1(IQR:1.67～2.76)vs.1.75 mmol·L?1(IQR:1.27～2.01)]和收缩压[130 mmHg(IQR:120～142)vs.122 mmHg(IQR:110～137),P<0.001]显著高于没有糖尿病的患者(P<0.001).2型糖尿病和其他代谢性疾病共存于COVID-19患者中,这可能会增加发病率并加重COVID-19的病情.血糖和脂质代谢的最佳管理是确保更好的临床结果的关键.对于患有糖尿病及其他基础和慢性代谢性疾病的COVID-19患者,应提高临床警惕性.“,”Diabetes and its related metabolic disorders have been reported as the leading comorbidities in patients with coronavirus disease 2019 (COVID-19). This clinical study aims to investigate the clinical features, radiographic and laboratory tests, complications, treatments, and clinical outcomes in COVID-19 patients with or without diabetes. This retrospective study included 208 hospitalized patients (≥45 years old) with laboratory-confirmed COVID-19 during the period between 12 January and 25 March 2020. Information from the medical record, including clinical features, radiographic and laboratory tests, complications, treat-ments, and clinical outcomes, were extracted for the analysis. 96 (46.2％) patients had comorbidity with type 2 diabetes. In COVID-19 patients with type 2 diabetes, the coexistence of hypertension (58.3％ vs 31.2％), coronary heart disease (17.1％vs 8.0％), and chronic kidney diseases (6.2％vs 0％) was significantly higher than in COVID-19 patients without type 2 diabetes. The frequency and degree of abnormalities in computed tomography (CT) chest scans in COVID-19 patients with type 2 diabetes were markedly increased, including ground-glass opacity (85.6％ vs 64.9％, P < 0.001) and bilateral patchy shadowing (76.7％ vs 37.8％, P <0.001). In addition, the levels of blood glucose (7.23 mmol·L-1 (interquartile range (IQR):5.80–9.29) vs 5.46 mmol·L-1 (IQR:5.00–6.46)), blood low-density lipoprotein cholesterol (LDL-C) (2.21 mmol·L-1 (IQR:1.67–2.76) vs 1.75 mmol·L-1 (IQR:1.27–2.01)), and systolic pressure (130 mmHg (IQR:120–142) vs 122 mmHg (IQR:110–137)) (1 mmHg=133.3 Pa) in COVID-19 patients with diabetes were significantly higher than in patients without diabetes (P<0.001). The coexistence of type 2 diabetes and other metabolic disorders is common in patients with COVID-19, which may potentiate the morbidity and aggravate COVID-19 progression. Optimal management of the metabolic hemostasis of glucose and lipids is the key to ensuring better clinical outcomes. Increased clinical vigilance is warranted for COVID-19 patients with diabetes and other metabolic diseases that are fundamental and chronic conditions.